Fig 1: NAC treatment inhibits HSPA6 expression in RSV-infected BEAS-2B cells. (a), The volcano plot showing differentially expressed genes between BEAS-2B cells stimulated with UV-inactivated RSV and BEAS-2B cells stimulated with the bronchial pathogen RSV. (b), Quantitative real-time PCR was performed to determine the mRNA expression of HSPA6 in RSV-infected BEAS-2B cells with or without NAC treatment. (c) Immunoblots of HSPA6 protein and their densitometric analysis in RSV-infected BEAS-2B cells with or without NAC treatment. ∗ indicates p < 0.01.
Fig 2: HSPA6 is up‐regulated in GC. (A) The expression of HSPA6 in STAD cell lines from the CCLE database. (B) RT‐qPCR results showing HSPA6 mRNA levels in AGS and NUGC2 cells respectively transfected with HSPA6 overexpression and siRNA constructs. (C) Immunoblot showing HSPA6 protein in the indicated cell lines and (D) the relative expression levels. (E) The growth curve of the indicated cell lines. (F) Heatmap showing the top 20 genes correlated with HSPA6 expression in STAD cell lines from CCLE. (G) The significantly enriched KEGG pathways of HSPA6‐related genes. (H) Immunoblots showing cyclin B1, YAP and p‐YAP proteins in the indicated cell lines and (I) their relative expression levels.
Fig 3: HSPA6 overexpression predicts poor survival in GC. (A, B) Representative images showing (A) low and (B) high in situ expression of HSPA6 in GC tissues; (C) Sankey diagram of TNM stage, HSPA6 expression and Ming classification; (D) restricted cubic splines for best cutoff point; (E) Kaplan–Meier overall survival curves of HSPA6high and HSPAlow in EGC and IGC groups; (F) prognostic nomogram for GC based on HSPA6 expression and clinicopathological variables; (G, H) straight line graph (G) and time‐dependent receiver operating characteristic (ROC) curves (H) for evaluating the predictive power of the nomogram.
Fig 4: HSPA6 is up‐regulated in GC. (A) The expression of HSPA6 in different cancers from the Oncomine database. (B–D) The expression of HSPA6 in STAD from (B) Oncomine database, (C) UALCAN and (D) GEPIA. (E) HSPA6 mRNA levels in STAD and normal tissues. (F) Immunoblot showing expression of HSPA6 protein in STAD and normal tissues and (G) the relative expression levels.
Fig 5: HSPA6 is associated with the proliferation of GC. (A) Heatmap showing the top 10 genes correlated to HSPA6 in the TCGA‐STAD dataset. (B) The significantly enriched KEGG pathways of HSPA6‐related genes. (C) The significantly enriched Hallmark functions of HSPA6‐related genes. (D) The proliferation of cells between the control and sh‐HSPA6 group was measured by 5‐ethynyl‐20‐deoxyuridine (EdU). (E) Representative images of tumor tissues in each group were shown.
Supplier Page from Abcam for Anti-HSPA6 antibody